| 柳冬兵,费侃强,刘加新,徐甦.加味温土汤治疗脾胃虚弱型慢性萎缩性胃炎的临床疗效研究[J].浙江中西医结合杂志,2025,35(9): |
| 加味温土汤治疗脾胃虚弱型慢性萎缩性胃炎的临床疗效研究 |
| Study on the clinical efficacy of modified Wentu Decoction in the treatment of chronic atrophic gastritis due to spleen and stomach weakness |
| 投稿时间：2024-11-29 修订日期：2025-07-06 |
| DOI： |
| 中文关键词: 加味温土汤 慢性萎缩性胃炎 临床疗效 胃功能 病理积分 |
| 英文关键词:Modified Wentu Decoction chronic atrophic gastritis clinical efficacy gastric function pathological score |
| 基金项目:浙江中医药大学校级科研项目附属医院科研专项(2021FSYYZY39)；浙江省徐甦名老中医专家传承工作室建设项目(GZS2021035) |
|
| 摘要点击次数: 105 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的:观察加味温土汤治疗慢性萎缩性胃炎(CAG)的临床疗效。方法:选取符合纳入及排除标准的80例CAG患者,随机分为治疗组和对照组,每组各40例,治疗组口服加味温土汤,对照组口服叶酸,治疗24周后比较两组患者的中医症候积分、血清胃功能及胃镜病理积分变化情况。结果:两组均能有效降低主症(胃痛、胃胀)、次症(食欲减退、乏力、大便稀溏)及症状总积分(P＜0.05),但治疗组在降低次症及总积分方面明显优于对照组(P＜0.05)；治疗组临床疗效总有效率95%,高于对照组的80%(P＜0.05)；两组均能有效提高胃蛋白酶原Ⅰ(PGⅠ)、PGR(胃蛋白酶原Ⅰ/胃蛋白酶原Ⅱ比值)、胃泌素17(G-17)水平,降低胃蛋白酶原Ⅱ(PGⅡ)水平(P＜0.05),但治疗组明显优于对照组(P＜0.05)；两组均能有效改善胃粘膜萎缩及炎症程度(P＜0.05),但治疗组优于对照组(P＜0.05),治疗组可有效改善胃粘膜肠上皮化生程度(P＜0.05),对照组改善不明显(P＞0.05)。结论:加味温土汤能有效改善CAG患者的临床症状,改善胃功能及胃粘膜的病理状态,提高临床疗效。 |
| 英文摘要: |
| Objective: To observe the clinical efficacy of modified Wentu Decoction in the treatment of chronic atrophic gastritis (CAG). Methods: 80 CAG patients who met the inclusion and exclusion criteria were selected and randomly divided into a treatment group and a control group, with 40 cases in each group. The treatment group was orally administered flavored Wentu Decoction, and the control group was orally administered folic acid. The two groups of patients were compared after 24 weeks of treatment. Changes in TCM symptom scores, serum gastric function and gastroscopy pathology scores.Results: Both groups were able to effectively reduce the main symptoms (stomach pain, bloating), secondary symptoms (loss of appetite, fatigue, loose stools) and total symptom score (P<0.05), However, the treatment group was significantly better than the control group in reducing secondary symptoms and total scores (P<0.05); the total clinical efficacy rate of the treatment group was 95%, higher than 80% of the control group (P<0.05); both groups could effectively increase pepsinogen Ⅰ (PG Ⅰ), PGR (gastric Proteaseogen Ⅰ/pepsinogen Ⅱ ratio), gastrin 17 (G-17) level, reduced pepsinogen Ⅱ (PG Ⅱ) level (P＜0.05), but the treatment group was significantly better than the control group (P＜0.05) ; Both groups can effectively improve the degree of gastric mucosal atrophy and inflammation (P<0.05), but the treatment group is better than the control group (P<0.05). The treatment group can effectively improve the degree of gastric mucosal intestinal metaplasia (P<0.05). There was no obvious improvement in the control group (P>0.05).Conclusion: Modified Wentu Decoction can effectively improve the clinical symptoms of CAG patients, improve gastric function and the pathological state of gastric mucosa, and improve clinical efficacy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
